ENCell designated as commercial cell processing center for CAR-T by global pharma company
Predicted impact: Low
Designation as a CAR-T processing center; no contract size or revenue share given.
ENCell이엔셀
456070 · KOSDAQ · ₩456070 · 이엔셀
₩4,590▼ ₩75 (1.61%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y −64.17%
- Market cap
- ₩51B
- Enterprise value
- ₩29B
- P/E
- —
- P/B
- 1.8×
- Dividend yield
- 0.0%
- ROE
- −70.4%
- Net margin
- −471.2%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−78.1% from the high
₩4,585Today: ₩4,585 – ₩4,820₩20,950
Returns
- 1W−8.2%
- 1M−22.5%
- 3M−17.9%
- 6M−72.1%
- YTD−74.8%
- 1Y−64.2%
- Volume today
- 32,467
- 0.5× the 20-day average
- Traded today
- ₩152M
- Listed shares
- 11,029,517
- EPS (12 months)
- −₩1,779
- Earnings yield −38.8%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 36 of 100 (50 is a normal day for this stock).
- SentimentPositiveNews: A new designation with a global pharma partner is a positive development. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-22.2% over the last month; the price is below its 20-day average.
- News impactLow1 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
ENCell stock overview
ENCell (이엔셀, KRX: 456070) is listed on KOSDAQ, in the Biotech & Pharma sector. The company develops and manufactures advanced biopharmaceuticals under two business models: contract development and manufacturing (CDMO) for cell therapies, gene therapies, and organoid-based treatments, and development of next-generation cell and gene therapy drugs. Its shares closed at ₩4,590 on Oct 27, 2026, down 1.61% on the day, giving it a market value of ₩51B.
Key facts
- Market cap
- ₩51B
- Sector
- Biotech & Pharma
- Latest price change
- −1.61%
- As of
- Oct 27, 2026
- Main business
- The company develops and manufactures advanced biopharmaceuticals under two business models: contract development and manufacturing (CDMO) for cell therapies, gene therapies, and organoid-based treatments, and development of next-generation cell and gene therapy drugs.
Quick answers about ENCell
- What does ENCell do?
- The company develops and manufactures advanced biopharmaceuticals under two business models: contract development and manufacturing (CDMO) for cell therapies, gene therapies, and organoid-based treatments, and development of next-generation cell and gene therapy drugs. Its CDMO services cover cell and viral vector production, research consulting, and quality analysis for clients developing advanced biologic drugs. Its drug development focuses on EN001, a mesenchymal stem cell therapy candidate for Charcot-Marie-Tooth disease, Duchenne muscular dystrophy, and sarcopenia, and it operates three GMP facilities in Korea.
- What is the market cap of ENCell?
- The market capitalisation of ENCell was ₩51B at the close on Oct 27, 2026.
- Who are the largest shareholders of ENCell?
- According to the latest official filings, the largest reported holders are Jang Jong-wook (32.60%, as of Aug 24, 2026); One & Partners (12.43%, as of Aug 27, 2026); NH Investment & Securities (5.71%, as of Apr 15, 2026).
- When is the next earnings report from ENCell?
- Korean companies rarely announce results dates in advance. Based on when ENCell filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
The company develops and manufactures advanced biopharmaceuticals under two business models: contract development and manufacturing (CDMO) for cell therapies, gene therapies, and organoid-based treatments, and development of next-generation cell and gene therapy drugs. Its CDMO services cover cell and viral vector production, research consulting, and quality analysis for clients developing advanced biologic drugs. Its drug development focuses on EN001, a mesenchymal stem cell therapy candidate for Charcot-Marie-Tooth disease, Duchenne muscular dystrophy, and sarcopenia, and it operates three GMP facilities in Korea.
Written by AI from the company's latest annual report.
- Korean name
- 이엔셀
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 장종욱
- Founded
- Mar 2018
- Listed
- Aug 2024
- Listed shares
- 11,029,517
- Fiscal year ends
- Month 12
- Website
- www.encellinc.com/
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent news
Recent filings
See all- 5%+ holding reportAug 27, 2026
- 5%+ holding reportAug 24, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Adjustment of Conversion Price (1st Series)Jul 13, 2026
- Amended: Major management matter relevant to investorsJul 10, 2026
Titles in Korean until English translations are added.
Also known as: ENCell / 이엔셀 / 456070 / KRX:456070
Source: KRX statistical information